Semax

The earlier profile gives Semax as the seven-residue sequence Met-Glu-His-Phe-Pro-Gly-Pro. It also discusses N-terminal acetylation. A modified terminal form must be named explicitly; it should not silently be treated as interchangeable with the unmodified sequence.

The tables retain the earlier example parameters and certificate format. Their masses and results are not verified specifications for every material called Semax. The intended form needs to be settled before comparing analytical results.

The described Fmoc (a temporary chemical protecting group) route assembles the chain on a solid support. The old account pays attention to protection and to oxidation around methionine during assembly, cleavage and recovery. Cleavage scavengers are included to reduce unwanted reactions.

Where acetylation is part of the intended target, the record needs evidence of its completion and a method for the unmodified species. It is a form-specific manufacturing choice, not a blanket claim about all Semax material.

The purification method needs to distinguish the intended form from oxidation products, deletion sequences and other close impurities. Methionine sulfoxide is the oxidised variant highlighted in the older account. Analytical scouting and fraction tests establish useful collection boundaries.

The earlier route then removes solvents and counterions before freeze-drying. Formulation, filling, stoppering and crimping need documented controls. Light protection and minimising unwanted oxidation remain relevant beyond the first purification step.

Identity testing needs agreement between mass, chromatographic comparison and the specified molecular form. Purity and quantitative content remain separate. Stability-indicating methods must show changes in the target and the relevant impurities rather than hide them under one peak.

The old panel also covers water, residual solvents, counterions and microbiological quality. Its sample certificate contains illustrative values. It is a model for reporting fields, not a real batch release certificate or evidence of a supplier’s performance.

The older programme follows oxidation, light effects, temperature and formulation changes. Stress studies help identify degradation products; long-term studies support storage claims. An example schedule alone cannot establish shelf life.

Powder and solution stability require separate measurement. Storage alarms, shipping qualification, receiving checks and protective packaging belong in the actual material’s handling record.

The manufacturing record should explain the terminal form, key reagent lots, oxidation controls, in-process results, selected fractions and drying conditions. Yield reconciliation, deviations and authorised release connect that process history with the CoA. Electronic records need controlled access and a traceable audit trail.

FDA’s page current as of April 22, 2026 lists semax among substances nominated but withdrawn. That does not clear it for compounding or establish approval. A public Oath catalogue entry is a separate, limited fact.

Semax tables retain the earlier manufacturing examples. No Semax table here validates an operating procedure, release limit or supplier result. The Semax examples have no supporting batch raw data; use them to identify document fields, not to infer measured performance.

Semax source links are retained below. These references give context for Semax manufacturing; they do not validate the numerical examples. Duplicate Semax source links retain the citation record.

1. cGMP regulations for peptide therapeutics
2. ICH Q7 guidelines for API manufacturing
3. FDA guidance on lyophilization of parenteral products
4. USP <1225> validation of compendial procedures
5. FDA cGMP requirements
6. U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice (CGMP) Regulations for Drugs. 21 CFR Parts 210 and 211. Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
7. International Council for Harmonisation (ICH). (2023). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Available at: https://www.ich.org/page/quality-guidelines
8. U.S. Food and Drug Administration. (2022). Guidance for Industry: Lyophilization of Parenteral Products. Center for Drug Evaluation and Research. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-lyophilization-parenteral-products
9. United States Pharmacopeia. (2024). USP <1225> Validation of Compendial Procedures. Available at: https://www.usp.org/validation
10. International Council for Harmonisation (ICH). (2023). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Available at: https://www.ich.org/page/quality-guidelines
11. International Council for Harmonisation (ICH). (2023). ICH Q1B: Photostability Testing of New Drug Substances and Products. Available at: https://www.ich.org/page/quality-guidelines
12. International Council for Harmonisation (ICH). (2023). ICH Q3C(R6): Impurities: Guideline for Residual Solvents. Available at: https://www.ich.org/page/quality-guidelines
13. United States Pharmacopeia. (2024). USP <788> Particulate Matter in Injections and USP <790> Visible Particulates in Injections. Available at: https://www.usp.org
14. U.S. Food and Drug Administration. (2023). Facts about the Current Good Manufacturing Practices (CGMPs). Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps